Accéder au contenu
Merck
Toutes les photos(1)

Documents

36-008

Sigma-Aldrich

Anti-α-Synuclein Antibody, clone Syn211

ascites fluid, clone Syn211, Upstate®

Synonyme(s) :

Anti-NACP, Anti-PARK1, Anti-PARK4, Anti-PD1

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
Toutes les photos(1)

About This Item

Code UNSPSC :
12352203
eCl@ss :
32160702
Nomenclature NACRES :
NA.41

Source biologique

mouse

Niveau de qualité

100

Forme d'anticorps

ascites fluid

Type de produit anticorps

primary antibodies

Clone

Syn211, monoclonal

Espèces réactives

human

Conditionnement

antibody small pack of 25 μL

Fabricant/nom de marque

Upstate®

Technique(s)

immunohistochemistry: suitable
immunoprecipitation (IP): suitable
western blot: suitable

Numéro d'accès NCBI

NM_000345.2
NM_007308.1

Numéro d'accès UniProt

P37840

Conditions d'expédition

ambient

Modification post-traductionnelle de la cible

unmodified

Informations sur le gène

human ... SNCA(6622)

Spécificité

α-Synuclein

Immunogène

full-length recombinant human α-Synuclein

Application

Detect α-Synuclein using this Anti-α-Synuclein Antibody, clone Syn211 validated for use in IP, WB, IH.
Research Category
Neuroscience
Research Sub Category
Neurodegenerative Diseases

Qualité

Routinely evaluated by immunoblot on Alzheimer′s diseased human whole brain lysates.

Description de la cible

~14.5kDa

Liaison

Replaces: 04-1053

Forme physique

Ascites

Stockage et stabilité

2 years at -20°C

Autres remarques

2024 CiteAb Award Winner for Supplier Succeeding in Parkinson′s Research

Informations légales

UPSTATE is a registered trademark of Merck KGaA, Darmstadt, Germany

Clause de non-responsabilité

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Not finding the right product?  

Try our Outil de sélection de produits.

En option

Réf. du produit
Description
Tarif

Code de la classe de stockage

12 - Non Combustible Liquids

Classe de danger pour l'eau (WGK)

WGK 1

Point d'éclair (°F)

Not applicable

Point d'éclair (°C)

Not applicable

Certificats d'analyse (COA)

Recherchez un Certificats d'analyse (COA) en saisissant le numéro de lot du produit. Les numéros de lot figurent sur l'étiquette du produit après les mots "Lot" ou "Batch".

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Jay S Schneider et al.
Molecular and cellular neurosciences, 120, 103729-103729 (2022-04-22)
Among the pathological events associated with the dopaminergic neurodegeneration characteristic of Parkinson's disease (PD) are the accumulation of toxic forms of α-synuclein and microglial activation associated with neuroinflammation. Although numerous other processes may participate in the pathogenesis of PD, the
Sarah M O'Donovan et al.
Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society, 32(1), e13726-e13726 (2019-10-03)
A hallmark feature of Parkinson's disease (PD) is the build-up of α-synuclein protein aggregates throughout the brain; however α-synuclein is also expressed in enteric neurons. Gastrointestinal (GI) symptoms and pathology are frequently reported in PD, including constipation, increased intestinal permeability
Sandra Cuellar-Baena et al.
Journal of neurochemistry, 137(5), 806-819 (2016-01-27)
In this study, we used proton-localized spectroscopy ((1) H-MRS) for the acquisition of the neurochemical profile longitudinally in a novel rat model of human wild-type alpha-synuclein (α-syn) over-expression. Our goal was to find out if the increased α-syn load in
Rachel Kelly et al.
Molecules (Basel, Switzerland), 27(2) (2022-01-22)
Since the discovery of α-synuclein as the major component in Lewy bodies, research into this protein in the context of Parkinson's disease pathology has been exponential. Cannabinoids are being investigated as potential therapies for Parkinson's disease from numerous aspects, but
Lien Veys et al.
Frontiers in aging neuroscience, 12, 614587-614587 (2021-02-02)
Although very different in etiology and symptoms, numerous neurodegenerative diseases can be classified as proteinopathies. More so, evidence indicates that the key misfolded proteins at the basis of different neuropathies might share common mechanisms of propagation. As such, the prion-like
Afficher tous les articles scientifiques apparentés

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique